mianserin has been researched along with Obesity in 5 studies
Mianserin: A tetracyclic compound with antidepressant effects. It may cause drowsiness and hematological problems. Its mechanism of therapeutic action is not well understood, although it apparently blocks alpha-adrenergic, histamine H1, and some types of serotonin receptors.
mianserin : A dibenzoazepine (specifically 1,2,3,4,10,14b-hexahydrodibenzo[c,f]pyrazino[1,2-a]azepine) methyl-substituted on N-2. Closely related to (and now mostly superseded by) the tetracyclic antidepressant mirtazapinean, it is an atypical antidepressant used in the treatment of depression throughout Europe and elsewhere.
Obesity: A status with BODY WEIGHT that is grossly above the recommended standards, usually due to accumulation of excess FATS in the body. The standards may vary with age, sex, genetic or cultural background. In the BODY MASS INDEX, a BMI greater than 30.0 kg/m2 is considered obese, and a BMI greater than 40.0 kg/m2 is considered morbidly obese (MORBID OBESITY).
| Excerpt | Relevance | Reference |
|---|---|---|
| " Mirtazapine, a widely used antidepressant, induces adverse metabolic effects such as an increase in body weight." | 5.12 | Effect of mirtazapine treatment on body composition and metabolism. ( Deisenhammer, EA; Ebenbichler, CF; Engl, J; Hinterhuber, H; Kramer-Reinstadler, K; Laimer, M; Lechner-Schoner, T; Patsch, JR; Rauchenzauner, M; Strauss, R, 2006) |
| "Fluoxetine was the reference treatment option in the medication models." | 1.39 | Influence of body mass index on the choice of therapy for depression and follow-up care. ( Arterburn, D; Bogart, A; Boudreau, DM; Haneuse, S; Simon, G; Theis, MK; Westbrook, E, 2013) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 1 (20.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 3 (60.00) | 29.6817 |
| 2010's | 1 (20.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Boudreau, DM | 1 |
| Arterburn, D | 1 |
| Bogart, A | 1 |
| Haneuse, S | 1 |
| Theis, MK | 1 |
| Westbrook, E | 1 |
| Simon, G | 1 |
| Zarse, K | 1 |
| Ristow, M | 1 |
| Fisfalen, ME | 1 |
| Hsiung, RC | 1 |
| Laimer, M | 1 |
| Kramer-Reinstadler, K | 1 |
| Rauchenzauner, M | 1 |
| Lechner-Schoner, T | 1 |
| Strauss, R | 1 |
| Engl, J | 1 |
| Deisenhammer, EA | 1 |
| Hinterhuber, H | 1 |
| Patsch, JR | 1 |
| Ebenbichler, CF | 1 |
| Cook, RF | 1 |
| Howard, AN | 1 |
| Mills, IH | 1 |
2 trials available for mianserin and Obesity
| Article | Year |
|---|---|
Effect of mirtazapine treatment on body composition and metabolism.
Topics: Adipose Tissue; Adult; Antidepressive Agents, Tricyclic; Blood Glucose; Body Composition; Body Fat D | 2006 |
Low-dose mianserin as adjuvant therapy in obese patients treated by a very-low-calorie diet.
Topics: Adolescent; Adult; Clinical Trials as Topic; Dibenzazepines; Double-Blind Method; Female; Humans; Ma | 1981 |
3 other studies available for mianserin and Obesity
| Article | Year |
|---|---|
Influence of body mass index on the choice of therapy for depression and follow-up care.
Topics: Adolescent; Adult; Aged; Antidepressive Agents; Body Mass Index; Choice Behavior; Cohort Studies; De | 2013 |
Antidepressants of the serotonin-antagonist type increase body fat and decrease lifespan of adult Caenorhabditis elegans.
Topics: Adipose Tissue; Animals; Antidepressive Agents; Caenorhabditis elegans; Caenorhabditis elegans Prote | 2008 |
Glucose dysregulation and mirtazapine-induced weight gain.
Topics: Adult; Antidepressive Agents, Tricyclic; Blood Glucose; Body Mass Index; Cocaine-Related Disorders; | 2003 |